The effects of glucagon‐like peptide (GLP)‐1 receptor agonists on weight and glycaemic control in Prader–Willi syndrome: A systematic review

Objective The mainstay management of hyperphagia and obesity in Prader–Willi syndrome (PWS) relies on dietary restrictions, strict supervision and behavioural modifications, which can be stressful for the patient and caregiver. There is no established pharmacological strategy to manage this aspect o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical endocrinology (Oxford) 2022-02, Vol.96 (2), p.144-154
Hauptverfasser:	Ng, Nicholas Beng Hui, Low, Yue Wey, Rajgor, Dimple Dayaram, Low, Jia Ming, Lim, Yvonne Yijuan, Loke, Kah Yin, Lee, Yung Seng
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Agonists Appetite Body mass index diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Dietary restrictions exenatide GLP-1 receptor agonists Glucagon Glucagon-Like Peptide 1 Glucagon-Like Peptide-1 Receptor glucagon‐like peptide 1 receptor agonists Glycemic Control Humans Hyperphagia liraglutide Liraglutide - therapeutic use Literature reviews Obesity Peptides Prader-Willi syndrome Prader-Willi Syndrome - drug therapy Satiety Systematic review Weight control Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!